Preeclampsia Clinical Trial
— PREMETOfficial title:
Prevention of Pre-eclampsia Using Metformin: a Randomized Control Trial
This is an open label, randomized control trial (RCT) in which high risk for pre-eclampsia pregnant subjects will be randomly assigned to either an intervention group (metformin 1 gm twice daily plus aspirin 100 mg per day and standard of care) versus control group (aspirin 100 mg per day and standard of care) that will be administered between 11 to 13 weeks of gestation until delivery . Only women at high risk of pre-eclampsia as defined by the ACOG practice bulletin will be included (see inclusion criteria). Patient assignment will not be blinded as control group will not be given a placebo; the data will be analyzed on an intention to treat basis. Enrolled subjects will be followed throughout pregnancy and up to 30 days post-delivery (as per hospital practice).
Status | Not yet recruiting |
Enrollment | 414 |
Est. completion date | December 30, 2023 |
Est. primary completion date | April 24, 2023 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 45 Years |
Eligibility | Inclusion Criteria: - Confirmed pregnancy - Gestational age < 12+0 weeks - Live fetus at time of booking ultrasound scan (between 11+0 and 13+6 weeks of gestation) - To be considered as high risk of preeclampsia Exclusion Criteria: - Age under 18 years - Hyperemesis gravidarum - Unable to sign the consent form - Type 1 or 2 diabetes mellitus - Early gestational diabetes - Auto-immune disease - Fetal abnormality identified at time of scanning (between 11+0 and 13+6 weeks of gestation) - Bleeding disorder - Peptic ulcer - Hypersensitivity to aspirin or metformin - Long use of NSAIDS before initiation of intervention - Contraindication to metformin or aspirin and participation in another concurrent trial. |
Country | Name | City | State |
---|---|---|---|
Qatar | Women Wellness and Research Center | Doha |
Lead Sponsor | Collaborator |
---|---|
Hamad Medical Corporation | Sidra Medical and Research Center |
Qatar,
Achen MG, Gad JM, Stacker SA, Wilks AF. Placenta growth factor and vascular endothelial growth factor are co-expressed during early embryonic development. Growth Factors. 1997;15(1):69-80. — View Citation
Alqudah A, McKinley MC, McNally R, Graham U, Watson CJ, Lyons TJ, McClements L. Risk of pre-eclampsia in women taking metformin: a systematic review and meta-analysis. Diabet Med. 2018 Feb;35(2):160-172. doi: 10.1111/dme.13523. — View Citation
Bartsch E, Medcalf KE, Park AL, Ray JG; High Risk of Pre-eclampsia Identification Group. Clinical risk factors for pre-eclampsia determined in early pregnancy: systematic review and meta-analysis of large cohort studies. BMJ. 2016 Apr 19;353:i1753. doi: 10.1136/bmj.i1753. Review. — View Citation
Bates DO. An unexpected tail of VEGF and PlGF in pre-eclampsia. Biochem Soc Trans. 2011 Dec;39(6):1576-82. doi: 10.1042/BST20110671. Review. — View Citation
Bianco A, Stone J, Lynch L, Lapinski R, Berkowitz G, Berkowitz RL. Pregnancy outcome at age 40 and older. Obstet Gynecol. 1996 Jun;87(6):917-22. — View Citation
Brownfoot FC, Hastie R, Hannan NJ, Cannon P, Tuohey L, Parry LJ, Senadheera S, Illanes SE, Kaitu'u-Lino TJ, Tong S. Metformin as a prevention and treatment for preeclampsia: effects on soluble fms-like tyrosine kinase 1 and soluble endoglin secretion and endothelial dysfunction. Am J Obstet Gynecol. 2016 Mar;214(3):356.e1-356.e15. doi: 10.1016/j.ajog.2015.12.019. Epub 2015 Dec 22. — View Citation
Butalia S, Gutierrez L, Lodha A, Aitken E, Zakariasen A, Donovan L. Short- and long-term outcomes of metformin compared with insulin alone in pregnancy: a systematic review and meta-analysis. Diabet Med. 2017 Jan;34(1):27-36. doi: 10.1111/dme.13150. Epub 2016 Jun 8. Review. — View Citation
Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M, Fahrig M, Vandenhoeck A, Harpal K, Eberhardt C, Declercq C, Pawling J, Moons L, Collen D, Risau W, Nagy A. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature. 1996 Apr 4;380(6573):435-9. — View Citation
Carmeliet P, Moons L, Luttun A, Vincenti V, Compernolle V, De Mol M, Wu Y, Bono F, Devy L, Beck H, Scholz D, Acker T, DiPalma T, Dewerchin M, Noel A, Stalmans I, Barra A, Blacher S, VandenDriessche T, Ponten A, Eriksson U, Plate KH, Foidart JM, Schaper W, Charnock-Jones DS, Hicklin DJ, Herbert JM, Collen D, Persico MG. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med. 2001 May;7(5):575-83. — View Citation
Chaiworapongsa T, Chaemsaithong P, Korzeniewski SJ, Yeo L, Romero R. Pre-eclampsia part 2: prediction, prevention and management. Nat Rev Nephrol. 2014 Sep;10(9):531-40. doi: 10.1038/nrneph.2014.103. Epub 2014 Jul 8. Review. — View Citation
Chang YS, Chen CN, Jeng SF, Su YN, Chen CY, Chou HC, Tsao PN, Hsieh WS. The sFlt-1/PlGF ratio as a predictor for poor pregnancy and neonatal outcomes. Pediatr Neonatol. 2017 Dec;58(6):529-533. doi: 10.1016/j.pedneo.2016.10.005. Epub 2017 May 10. — View Citation
Chappell LC, Enye S, Seed P, Briley AL, Poston L, Shennan AH. Adverse perinatal outcomes and risk factors for preeclampsia in women with chronic hypertension: a prospective study. Hypertension. 2008 Apr;51(4):1002-9. doi: 10.1161/HYPERTENSIONAHA.107.107565. Epub 2008 Feb 7. — View Citation
Chasan-Taber L, Silveira M, Waring ME, Pekow P, Braun B, Manson JE, Solomon CG, Markenson G. Gestational Weight Gain, Body Mass Index, and Risk of Hypertensive Disorders of Pregnancy in a Predominantly Puerto Rican Population. Matern Child Health J. 2016 Sep;20(9):1804-13. doi: 10.1007/s10995-016-1983-3. — View Citation
Chaussabel D, Baldwin N. Democratizing systems immunology with modular transcriptional repertoire analyses. Nat Rev Immunol. 2014 Apr;14(4):271-80. doi: 10.1038/nri3642. Review. — View Citation
Chiswick C, Reynolds RM, Denison F, Drake AJ, Forbes S, Newby DE, Walker BR, Quenby S, Wray S, Weeks A, Lashen H, Rodriguez A, Murray G, Whyte S, Norman JE. Effect of metformin on maternal and fetal outcomes in obese pregnant women (EMPOWaR): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2015 Oct;3(10):778-86. doi: 10.1016/S2213-8587(15)00219-3. Epub 2015 Jul 9. — View Citation
Dallaglio K, Bruno A, Cantelmo AR, Esposito AI, Ruggiero L, Orecchioni S, Calleri A, Bertolini F, Pfeffer U, Noonan DM, Albini A. Paradoxic effects of metformin on endothelial cells and angiogenesis. Carcinogenesis. 2014 May;35(5):1055-66. doi: 10.1093/carcin/bgu001. Epub 2014 Jan 13. — View Citation
De Leo V, Musacchio MC, Piomboni P, Di Sabatino A, Morgante G. The administration of metformin during pregnancy reduces polycystic ovary syndrome related gestational complications. Eur J Obstet Gynecol Reprod Biol. 2011 Jul;157(1):63-6. doi: 10.1016/j.ejogrb.2011.03.024. Epub 2011 May 6. — View Citation
Duckitt K, Harrington D. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. BMJ. 2005 Mar 12;330(7491):565. Epub 2005 Mar 2. Review. — View Citation
Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O'Shea KS, Powell-Braxton L, Hillan KJ, Moore MW. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature. 1996 Apr 4;380(6573):439-42. — View Citation
Gathiram P, Moodley J. Pre-eclampsia: its pathogenesis and pathophysiolgy. Cardiovasc J Afr. 2016 Mar-Apr;27(2):71-8. doi: 10.5830/CVJA-2016-009. Review. — View Citation
Gilbert C, Valois M, Koren G. Pregnancy outcome after first-trimester exposure to metformin: a meta-analysis. Fertil Steril. 2006 Sep;86(3):658-63. Epub 2006 Jul 31. Review. — View Citation
Goldman-Wohl D, Yagel S. Regulation of trophoblast invasion: from normal implantation to pre-eclampsia. Mol Cell Endocrinol. 2002 Feb 22;187(1-2):233-8. Review. — View Citation
Gu Y, Lewis DF, Wang Y. Placental productions and expressions of soluble endoglin, soluble fms-like tyrosine kinase receptor-1, and placental growth factor in normal and preeclamptic pregnancies. J Clin Endocrinol Metab. 2008 Jan;93(1):260-6. Epub 2007 Oct 23. — View Citation
Herraiz I, Simón E, Gómez-Arriaga PI, Martínez-Moratalla JM, García-Burguillo A, Jiménez EA, Galindo A. Angiogenesis-Related Biomarkers (sFlt-1/PLGF) in the Prediction and Diagnosis of Placental Dysfunction: An Approach for Clinical Integration. Int J Mol Sci. 2015 Aug 13;16(8):19009-26. doi: 10.3390/ijms160819009. Review. — View Citation
Jin ZG, Ueba H, Tanimoto T, Lungu AO, Frame MD, Berk BC. Ligand-independent activation of vascular endothelial growth factor receptor 2 by fluid shear stress regulates activation of endothelial nitric oxide synthase. Circ Res. 2003 Aug 22;93(4):354-63. Epub 2003 Jul 31. — View Citation
Kaufman MR, Brown TL. AMPK and Placental Progenitor Cells. Exp Suppl. 2016;107:73-79. Review. — View Citation
King BF. Ultrastructural differentiation of stromal and vascular components in early macaque placental villi. Am J Anat. 1987 Jan;178(1):30-44. — View Citation
Koga K, Osuga Y, Yoshino O, Hirota Y, Ruimeng X, Hirata T, Takeda S, Yano T, Tsutsumi O, Taketani Y. Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia. J Clin Endocrinol Metab. 2003 May;88(5):2348-51. — View Citation
Lautatzis ME, Goulis DG, Vrontakis M. Efficacy and safety of metformin during pregnancy in women with gestational diabetes mellitus or polycystic ovary syndrome: a systematic review. Metabolism. 2013 Nov;62(11):1522-34. doi: 10.1016/j.metabol.2013.06.006. Epub 2013 Jul 23. Review. — View Citation
Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004 Feb 12;350(7):672-83. Epub 2004 Feb 5. — View Citation
Li H, Gu B, Zhang Y, Lewis DF, Wang Y. Hypoxia-induced increase in soluble Flt-1 production correlates with enhanced oxidative stress in trophoblast cells from the human placenta. Placenta. 2005 Feb-Mar;26(2-3):210-7. — View Citation
Luttun A, Carmeliet P. Soluble VEGF receptor Flt1: the elusive preeclampsia factor discovered? J Clin Invest. 2003 Mar;111(5):600-2. — View Citation
Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003 Mar;111(5):649-58. — View Citation
Mostello D, Kallogjeri D, Tungsiripat R, Leet T. Recurrence of preeclampsia: effects of gestational age at delivery of the first pregnancy, body mass index, paternity, and interval between births. Am J Obstet Gynecol. 2008 Jul;199(1):55.e1-7. doi: 10.1016/j.ajog.2007.11.058. Epub 2008 Feb 15. — View Citation
Nagar T, Sharma D, Choudhary M, Khoiwal S, Nagar RP, Pandita A. The Role of Uterine and Umbilical Arterial Doppler in High-risk Pregnancy: A Prospective Observational Study from India. Clin Med Insights Reprod Health. 2015 Apr 15;9:1-5. doi: 10.4137/CMRH.S24048. eCollection 2015. — View Citation
Parker MW, Xu P, Li X, Vander Kooi CW. Structural basis for selective vascular endothelial growth factor-A (VEGF-A) binding to neuropilin-1. J Biol Chem. 2012 Mar 30;287(14):11082-9. doi: 10.1074/jbc.M111.331140. Epub 2012 Feb 7. — View Citation
Qiu C, Williams MA, Leisenring WM, Sorensen TK, Frederick IO, Dempsey JC, Luthy DA. Family history of hypertension and type 2 diabetes in relation to preeclampsia risk. Hypertension. 2003 Mar;41(3):408-13. Epub 2003 Feb 17. — View Citation
Rajakumar A, Chu T, Handley DE, Bunce KD, Burke B, Hubel CA, Jeyabalan A, Peters DG. Maternal gene expression profiling during pregnancy and preeclampsia in human peripheral blood mononuclear cells. Placenta. 2011 Jan;32(1):70-8. doi: 10.1016/j.placenta.2010.10.004. Epub 2010 Nov 13. — View Citation
Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. Diabetologia. 2017 Sep;60(9):1577-1585. doi: 10.1007/s00125-017-4342-z. Epub 2017 Aug 3. Review. — View Citation
Ribatti D. The discovery of the placental growth factor and its role in angiogenesis: a historical review. Angiogenesis. 2008;11(3):215-21. doi: 10.1007/s10456-008-9114-4. Epub 2008 Jun 21. — View Citation
Romero R, Erez O, Hüttemann M, Maymon E, Panaitescu B, Conde-Agudelo A, Pacora P, Yoon BH, Grossman LI. Metformin, the aspirin of the 21st century: its role in gestational diabetes mellitus, prevention of preeclampsia and cancer, and the promotion of longevity. Am J Obstet Gynecol. 2017 Sep;217(3):282-302. doi: 10.1016/j.ajog.2017.06.003. Epub 2017 Jun 12. Review. — View Citation
Rowan JA, Hague WM, Gao W, Battin MR, Moore MP; MiG Trial Investigators. Metformin versus insulin for the treatment of gestational diabetes. N Engl J Med. 2008 May 8;358(19):2003-15. doi: 10.1056/NEJMoa0707193. Erratum in: N Engl J Med. 2008 Jul 3;359(1):106. — View Citation
Shibuya M, Yamaguchi S, Yamane A, Ikeda T, Tojo A, Matsushime H, Sato M. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. Oncogene. 1990 Apr;5(4):519-24. — View Citation
Shibuya M. VEGF-VEGFR Signals in Health and Disease. Biomol Ther (Seoul). 2014 Jan;22(1):1-9. doi: 10.4062/biomolther.2013.113. Review. — View Citation
Sibai BM, Caritis S, Hauth J, Lindheimer M, VanDorsten JP, MacPherson C, Klebanoff M, Landon M, Miodovnik M, Paul R, Meis P, Dombrowski M, Thurnau G, Roberts J, McNellis D. Risks of preeclampsia and adverse neonatal outcomes among women with pregestational diabetes mellitus. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. Am J Obstet Gynecol. 2000 Feb;182(2):364-9. — View Citation
Simons M, Gordon E, Claesson-Welsh L. Mechanisms and regulation of endothelial VEGF receptor signalling. Nat Rev Mol Cell Biol. 2016 Oct;17(10):611-25. doi: 10.1038/nrm.2016.87. Epub 2016 Jul 27. Review. — View Citation
Skjaerven R, Wilcox AJ, Lie RT. The interval between pregnancies and the risk of preeclampsia. N Engl J Med. 2002 Jan 3;346(1):33-8. — View Citation
Skupski DW, Nelson S, Kowalik A, Polaneczky M, Smith-Levitin M, Hutson JM, Rosenwaks Z. Multiple gestations from in vitro fertilization: successful implantation alone is not associated with subsequent preeclampsia. Am J Obstet Gynecol. 1996 Oct;175(4 Pt 1):1029-32. — View Citation
Stepan H, Herraiz I, Schlembach D, Verlohren S, Brennecke S, Chantraine F, Klein E, Lapaire O, Llurba E, Ramoni A, Vatish M, Wertaschnigg D, Galindo A. Implementation of the sFlt-1/PlGF ratio for prediction and diagnosis of pre-eclampsia in singleton pregnancy: implications for clinical practice. Ultrasound Obstet Gynecol. 2015 Mar;45(3):241-6. doi: 10.1002/uog.14799. Review. — View Citation
Syngelaki A, Nicolaides KH, Balani J, Hyer S, Akolekar R, Kotecha R, Pastides A, Shehata H. Metformin versus Placebo in Obese Pregnant Women without Diabetes Mellitus. N Engl J Med. 2016 Feb 4;374(5):434-43. doi: 10.1056/NEJMoa1509819. — View Citation
Tan X, Li S, Chang Y, Fang C, Liu H, Zhang X, Wang Y. Effect of metformin treatment during pregnancy on women with PCOS: a systematic review and meta-analysis. Clin Invest Med. 2016 Sep 11;39(4):E120-31. Review. — View Citation
Tzima E, Irani-Tehrani M, Kiosses WB, Dejana E, Schultz DA, Engelhardt B, Cao G, DeLisser H, Schwartz MA. A mechanosensory complex that mediates the endothelial cell response to fluid shear stress. Nature. 2005 Sep 15;437(7057):426-31. — View Citation
Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M, Andreelli F. Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond). 2012 Mar;122(6):253-70. doi: 10.1042/CS20110386. Review. — View Citation
Walsh SW. What causes endothelial cell activation in preeclamptic women? Am J Pathol. 2006 Oct;169(4):1104-6. — View Citation
Wang Y, Zhao S. Vascular Biology of the Placenta. San Rafael (CA): Morgan & Claypool Life Sciences; 2010. — View Citation
Wang Z, Wang P, Liu H, He X, Zhang J, Yan H, Xu D, Wang B. Maternal adiposity as an independent risk factor for pre-eclampsia: a meta-analysis of prospective cohort studies. Obes Rev. 2013 Jun;14(6):508-21. doi: 10.1111/obr.12025. Epub 2013 Mar 26. Review. — View Citation
Yusuf AM, Kahane A, Ray JG. First and Second Trimester Serum sFlt-1/PlGF Ratio and Subsequent Preeclampsia: A Systematic Review. J Obstet Gynaecol Can. 2018 May;40(5):618-626. doi: 10.1016/j.jogc.2017.07.014. Epub 2017 Sep 15. — View Citation
Zhao LP, Sheng XY, Zhou S, Yang T, Ma LY, Zhou Y, Cui YM. Metformin versus insulin for gestational diabetes mellitus: a meta-analysis. Br J Clin Pharmacol. 2015 Nov;80(5):1224-34. doi: 10.1111/bcp.12672. Epub 2015 Jul 14. Review. — View Citation
Zhao M, Zhu Z, Liu C, Zhang Z. Dual-cutoff of sFlt-1/PlGF ratio in the stratification of preeclampsia: a systematic review and meta-analysis. Arch Gynecol Obstet. 2017 May;295(5):1079-1087. doi: 10.1007/s00404-017-4302-3. Epub 2017 Mar 17. Review. — View Citation
Zheng J, Shan PF, Gu W. The efficacy of metformin in pregnant women with polycystic ovary syndrome: a meta-analysis of clinical trials. J Endocrinol Invest. 2013 Nov;36(10):797-802. doi: 10.3275/8932. Epub 2013 Apr 12. — View Citation
Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ, Moller DE. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 2001 Oct;108(8):1167-74. — View Citation
Zhou Y, McMaster M, Woo K, Janatpour M, Perry J, Karpanen T, Alitalo K, Damsky C, Fisher SJ. Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. Am J Pathol. 2002 Apr;160(4):1405-23. — View Citation
Zhu B, Zhang L, Fan YY, Wang L, Li XG, Liu T, Cao YS, Zhao ZG. Metformin versus insulin in gestational diabetes mellitus: a meta-analysis of randomized clinical trials. Ir J Med Sci. 2016 May;185(2):371-81. doi: 10.1007/s11845-016-1414-x. Epub 2016 Feb 9. — View Citation
* Note: There are 63 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of PET | To compare the incidence of PET between the metformin group (intervention group) versus control group | Through study completion period (3 years) | |
Primary | Evaluating PIGF/sFlt-1 as a prognostic marker in PET in Qatar | Comparing PIGF/sFlt-1 ratio in both groups before and after developing PET | Through study completion period (3 years) | |
Secondary | PIGF/sFlt-1 as a prognostic marker in PET patients | Comparing PIGF/sFlt-1 ratio in PET patients who received metformin versus PET patient in the standard care group | Through study completion period (3 years) | |
Secondary | Maternal outcomes | Comparing gestational age at PET onset, gestation age at delivery and PET severity between study groups | Through study completion period (3 years) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03510286 -
Validation of a PrCr Dipstick Diagnostic Test in Ghana
|
||
Recruiting |
NCT03313024 -
Berlin-Brandenburg Pregnancy Cohort
|
||
Active, not recruiting |
NCT04990141 -
Molecular Screening Method for Preeclampsia (PREMOM)
|
||
Completed |
NCT02147626 -
Heart Health 4 Moms Trial to Reduce CVD Risk After Preeclampsia
|
N/A | |
Not yet recruiting |
NCT05999851 -
Multiparametric Assessment of Maternal Vascular Function in the Prediction of Hypertensive Disorders of Pregnancy
|
N/A | |
Recruiting |
NCT02923206 -
Proof-of-Concept Trial on Selective Removal of sFlt-1 in Pregnant Women With Preeclampsia Via Apheresis
|
N/A | |
Completed |
NCT02554604 -
Identifying HDL Composition and Function in Preeclamptic and Normal Pregnancies
|
||
Not yet recruiting |
NCT02541110 -
Prediction of Preeclampsia & Other Obstetric Complications by Serum Homocysteine & Doppler
|
N/A | |
Terminated |
NCT02558023 -
The Treatment of Hypertension Associated With Severe Preeclampsia (PE). A Trial of Urapidil Versus Nicardipine
|
Phase 3 | |
Completed |
NCT02384226 -
User Testing and Feedback for a Mobile Health Program for Postpartum Women: A Pilot Study
|
||
Completed |
NCT02854501 -
Second Trimester Maternal Serum Homocysteine Levels and Uterine Artery Doppler for Prediction of Preeclampsia and Placentation Disorders
|
||
Withdrawn |
NCT05016440 -
Lisinopril for Renal Protection in Postpartum Preeclamptic Women
|
N/A | |
Recruiting |
NCT02247297 -
Pancreatic Stone Protein (PSP) in Pregnant Women
|
||
Recruiting |
NCT02337049 -
Preeclampsia Subtypes and Surrogate Markers of CVD Risk
|
N/A | |
Completed |
NCT02238704 -
Cornell University-Micronutrient Initiative Calcium Supplementation Study
|
N/A | |
Completed |
NCT01195441 -
Prediction and Prevention of Preeclampsia by First Trimester Ultrasound
|
N/A | |
Withdrawn |
NCT01179542 -
The Involvement of Eukaryotic Translation Initiation Factor 4E (eIF4E) in Human Placental Implantation and in the Pathological Pregnancies: Preeclampsia and IUGR
|
N/A | |
Completed |
NCT00456118 -
Study of the Role of Tissular Maternofetal Alloimmunization in Placentation Pathologies
|
||
Recruiting |
NCT00117546 -
Cardiovascular and Autonomic Reactivity in Women With a History of Pre-eclampsia
|
Phase 4 | |
Completed |
NCT00787241 -
Platelet Count Trends in Pre-eclamptic Parturients
|
N/A |